89
Participants
Start Date
December 6, 2023
Primary Completion Date
October 31, 2026
Study Completion Date
October 31, 2026
4 cycles of ESA regimen with sandwiched radiotherapy
Pegaspargase, 2500U/m2, i.m. d1; etoposide, 200mg, p.o., d2-d4; Dexamethasone, 40mg, p.o. d2-d4；
2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase
Pegaspargase, 2500U/m2, IM, d1; PD-1 monoclonal antibody, 200mg, i.v. d2;
2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase
PD-1 monoclonal antibody, 200mg, i.v. d1
RECRUITING
Ruijin Hospital, Shanghai
Ruijin Hospital
OTHER